Ricevi le ultime notizie sulle azioni Assembly Biosciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ASMB

Ultime notizie per

Assembly Biosciences

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences Inc

Biotech

Earnings

Health Care

Press Releases

General

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics

News

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

ASMB

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

C4 Therapeutics

Coherus Oncology

Caribou Biosciences

Citius Oncology

Elicio Therapeutics

Forte Biosciences

Genfit

Genelux

Heron Therapeutics

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Invivyd

Seres Therapeutics

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Comments

Assembly Biosciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO